Study of BP-SCIG 20% for primary immune deficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of primary immunodeficiency with low antibodies, as defined by ESID criteria.
- You need to weigh at least 20 pounds (9.1 kg).
- If you already use IVIG every 3-4 weeks or SCIG monthly, you must have been on it for at least 4 months and have stable antibody levels. Or, you may be newly diagnosed and never treated, with very low antibody levels.
- You should not have had a serious bacterial infection or been hospitalized in the last 3 months.
- Women who can become pregnant must have a negative pregnancy test and use reliable birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
Hear when a new Primary Immunodeficiency Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.